Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Affimed (Group)

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAb® antibody platform. Affimed's product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13). Further novel product candidates are in development to treat solid tumors and autoimmune diseases. Affimed's proprietary and highly productive TandAb® technology enables the company to generate unique tetravalent, bispecific, fully human antibody formats that promise increased therapeutic potential and superior profiles compared to monoclonal antibodies. The private company Affimed, which employs 30 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg. About TandAbs®: TandAbs®, which were invented and developed by Affimed scientists, are tetravalent bispecific antibody formats that have two binding sites for each antigen. RECRUIT-TandAbs®, such as AFM11 and AFM13, bind to target molecules on the surface of tumor cells (CD19 and CD30, respectively) and can activate immune effector cells such as cytotoxic T-cells or natural killer (NK) cells. RECRUIT-TandAbs® possess the same avidity and affinity for each target as an IgG; however, the much higher potency of TandAbs® versus IgG is achieved by a more efficient binding to the immune effector cells. Combined with their bispecificity, this format represents a potent further development of therapeutic monoclonal antibodies and, potentially, a superior alternative to first generation antibody formats/scaffolds. A robust production process for TandAbs has been established with excellent stability of the drug product. Affimed has developed different kinds of TandAbs® for specific indications. While RECRUIT-TandAbs® are applied to oncology, BiBLOCK- and PROLONG-TandAbs® are developed for the treatment of autoimmune and inflammatory diseases. *


Period Start 2000-05-01 splitoff
  Predecessor DKFZ (German Cancer Research Center, GCRC)
Products Industry MAb, human, fully
  Industry 2 TandAb bispecific antibody
Persons Person Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
  Person 2 Fischer, Florian (MedVenture Partners 201305 Managing Director + Affimed CFO 201510)
Region Region Heidelberg
  Country Germany
  Street 582 Im Neuenheimer Feld
Technologiepark Heidelberg
  City 69120 Heidelberg
  Tel +49-6221-65307-0
    Address record changed: 2020-12-02
Basic data Employees D: 101 to 500 (2022-12-31)
  Currency EUR
  Annual sales 41,353,000 (revenue, consolidated (2022) 2022-12-31)
  Profit -86,004,000 (2022-12-31)
  Cash 190,286,000 (2022-12-31)
    * Document for »About Section«: 
Record changed: 2024-03-22


Picture [iito] [LSE] Business Portal 650x200px

More documents for Affimed (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top